Praveen Chandar Balraj, MD
Vascular Surgery · Queen Creek, AZNPI 1447562640
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.1% of the total across 271 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 30 manufacturers reported payments, led by W. L. Gore & Associates, Inc. at 32.2% of the total.
Across 271 payments — averaging $43.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- W. L. Gore & Associates, Inc.$4K
- Medtronic$3K
- Endologix LLC$2K
- Penumbra, Inc.$661
- Bolton Medical Inc$608
- Cook Medical LLC$373
- plus $2K from 24 others
What the payments were for
- Travel & lodging$5585%
- Food & beverage$11,06393%
- Education$2662%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| W. L. Gore & Associates, Inc. | 70 | $3,822 |
| Medtronic(2 entities) | 87 | $2,839 |
| Endologix LLC | 15 | $1,621 |
| Penumbra, Inc. | 8 | $661 |
| Bolton Medical Inc | 12 | $608 |
| Cook Medical LLC | 12 | $373 |
| Philips North America LLC | 15 | $322 |
| Shockwave Medical, Inc | 1 | $291 |
| Johnson & Johnson(2 entities) | 6 | $248 |
| Boston Scientific | 8 | $144 |
| Abbott | 2 | $126 |
| Cordis US CORP. | 5 | $116 |
| Angiodynamics, Inc. | 3 | $105 |
| Silk Road Medical, Inc. | 4 | $99 |
| Edwards Lifesciences | 4 | $86 |
| Inari Medical, Inc. | 2 | $79 |
| Davol Inc. | 1 | $54 |
| Lemaitre Vascular, Inc. | 3 | $49 |
| Reflow Medical Inc | 1 | $31 |
| BD | 1 | $26 |
| Cagent Vascular Inc | 1 | $26 |
| Pfizer | 2 | $24 |
| Dilon Technologies, Inc. | 1 | $21 |
| EKOS Corporation | 1 | $20 |
| Bard Peripheral Vascular, Inc. | 1 | $18 |
| Teleflex LLC | 1 | $17 |
| Stryker | 1 | $17 |
| Asahi Intecc USA, Inc. | 1 | $16 |
| KCI USA, Inc. | 1 | $14 |
| Smith+Nephew | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GORE TAG Thoracic Branch Endoprosthesis$707
- Torus Stent Graft System$662
- ENDOCROSS Device$662
- EXCLUDER AAA Endoprosthesis$509
- Ovation$414
- AFX$414
- Indigo System$306
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$291
- GORE TAG Thoracic Endoprosthesis$287
- ENDURANT IIS$259
- Endurant$249
- Alto Abdominal Stent Graft System$244
- EXCLUDER Conformable AAA Endoprosthesis with Active Control$225
- VIABAHN Endoprosthesis with Heparin Bioactive Surface$198
- Penumbra System$176
- IN.PACT Admiral$169
- Abre$166
- Zenith Alpha$163
- VIABAHN VBX Balloon Expandable Endoprosthesis$155
- ELLIPSYS VASCULAR ACCESS SYSTEM$154
How this compares
$11,887 in reported general payments places this provider in the 60th percentile of 105 vascular surgery providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 28 | $28,832 |
| EliquisApixaban | 12 | $8,509 |
| ClopidogrelClopidogrel Bisulfate | 60 | $902 |
| Cilostazol | 46 | $668 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 11 | $180 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 11 | $87 |
| Furosemide | 24 | $71 |
| Oxycodone Hcl | 13 | $50 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $248 | $28,83228 claims |
| PfizerEliquis | $24 | $8,50912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 105 vascular surgery providers in Arizona.
Other vascular surgery in Queen Creek
- Venkatesh RamaiahScottsdale$452K
- Jeromy BrinkPhoenix$392K
- Luis LeonPhoenix$185K
- Hammad AmerMesa$169K
- Baljeet UppalSun City$166K
- Scott BermanTuscon$150K
- Martin ZomayaPhoenix$139K
- Joshua BaldermanTucson$135K
- John PacanowskiTucson$85K
- Joseph VijungcoChandler$63K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.